Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Mariana Oncology is a biotechnology research industry.
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Complement Therapeutics operates as a preclinical stage company.
Amphista Therapeutics operates as a biopharmaceutical company.
Inversago Pharma is a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Gyroscope Therapeutics is a clinical-stage gene therapy company focused on developing therapies and treating diseases of the eye.
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.
Mestag Therapeutics is a biotechnology company that develops new therapies for diseases using fibroblast technology.
Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.
Slate Medicines develops therapeutics that target Pituitary Adenylate Cyclase-Activating Polypeptide for migraine treatment and prevention.
Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
Gate Bioscience is a biotechnology company that specializes in a small molecule modality to treat biology’s intractable diseases.
Braveheart Bio is a clinical-stage biotechnology company focused on developing precision therapies in the cardiovascular disease space.
Forbion Capital Partners has invested in 124 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 17 different industry categories.
Among tracked funding rounds, Dyne Therapeutics received $402.5M in a Post Ipo Equity round. Forbion Capital Partners's total known invested capital is $12.0B.
Forbion Capital Partners's average investment size is $96.6M across its portfolio of 124 companies.
Recent Forbion Capital Partners portfolio additions include Mariana Oncology, Dualyx, Complement Therapeutics, Amphista Therapeutics, Inversago Pharma. These companies were founded in 2020 or later.